Precision diagnostics for diseases that affect the brain and other organs brought closer by new ability to exclusively access contents of organ-derived extracellular vesicles in blood Peer-Reviewed Publication Wyss Institute for Biologically Inspired Engineering at Harvard image: The team’s overall goal was to be able to compare the amounts of α-synuclein protein contained in extracellular...
Tag: <span>Parkinson disease</span>
Post
Scientists use stem cells to recreate a hallmark of Parkinson’s disease in human neurons
Slide showing the development of Lewy bodies. Credit: Armin Bayati from Peter McPherson Lab, The Neuro Lewy bodies are a hallmark of Parkinson’s disease (PD) and other related neurological conditions. Understanding why and how they develop is critical to developing better treatments. A study from The Neuro (Montreal Neurological Institute-Hospital) of McGill University, in collaboration...
Post
Famed diabetes doctor reveals what’s next for Ozempic-like drugs
By Social Links forTracy SwartzPublished July 18, 2024, 2:00 p.m. ET Ozempic has been hailed as a game-changing weight loss wonder drug, but its superpowers seem to extend well beyond treating Type 2 diabetes. Canadian endocrinologist Daniel J. Drucker — a diabetes treatment pioneer whose work paved the way for Ozempic — is sharing what’s...
Post
Risk factors for the development of freezing of gait in Parkinson’s disease patients
By Dr. Chinta SidharthanDec 6 2023Reviewed by Lily Ramsey, LLM In a recent study published in the journal Npj Parkinson’s Disease, researchers meta-analyzed data obtained from a systematic review to understand the risk factors that influence the development of freezing of gait or FOG — a debilitating condition that occurs in some Parkinson’s disease patients....
Post
Dopamine agonists and dopamine reuptake inhibitors provide similar quality of life for Parkinson disease patients
For patients with Parkinson disease on levodopa therapy, patient-rated quality of life is similar for those receiving adjuvant therapy with dopamine agonists compared with dopamine reuptake inhibitors (DRIs); and among DRIs, monoamine oxidase type B (MAO-B) inhibitors are preferable to catechol-O-methyltransferase (COMT) inhibitors, according to a study published online Dec. 28 in JAMA Neurology. Richard Gray,...